Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prop 65 suit names 56 supplement firms

This article was originally published in The Tan Sheet

Executive Summary

The California attorney general alleges 56 multivitamin marketers violated the state's Proposition 65 by failing to warn that their products included lead. The AG filed the suit Dec. 23 after the Carrick Law Group sent notices to 74 companies the FDA identified as having lead in their multivitamins (1"The Tan Sheet" Aug. 11, 2008, p. 8). The complaint does not name 14 of the companies identified in FDA's study because they have fewer than 10 employees and are not subject to Prop 65, which requires companies to warn when products include chemicals that could cause cancer or reproductive problems

You may also be interested in...



FDA Survey Shows Lead Labeling Not Needed For Supplements – Stakeholders

FDA's survey of lead contamination in hundreds of women's and children's vitamin supplements found what many industry stakeholders expected - lead levels in vitamins are not a cause for concern

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel